protease-activated anti-CD3/anti-EGFR T-cell engager (Harpoon Therapeutics)

N/A

Report date: 2026/03/19 16:57:31

Base Information

Drug Nameprotease-activated anti-CD3/anti-EGFR T-cell engager (Harpoon Therapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsSerum albumin modulatorsEpidermal growth factor receptor erbB1 modulators
TargetsT cell surface glycoprotein CD3Epidermal growth factor receptor erbB1Serum albumin
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHarpoon Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMerck & Co IncAbbvie Inc
Inactive CompaniesHarpoon Therapeutics Inc
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A